Literature DB >> 90819

Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus.

M P Kiley, J V Lange, K M Johnson.   

Abstract

Entities:  

Mesh：

Year:  1979        PMID： 90819     DOI： 10.1016/s0140-6736(79)90659-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  30 in total

1.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

2.  Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene.

Authors:  S P Fisher-Hoch; J B McCormick; D Auperin; B G Brown; M Castor; G Perez; S Ruo; A Conaty; L Brammer; S Bauer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

3.  Exonuclease domain of the Lassa virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response.

Authors:  Stéphanie Reynard; Marion Russier; Alexandra Fizet; Xavier Carnec; Sylvain Baize
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

4.  Serological and biological evidence that Lassa-complex arenaviruses are widely distributed in Africa.

Authors:  M P Kiley; R Swanepoel; S W Mitchell; J V Lange; J P Gonzalez; J B McCormick
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

5.  A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.

Authors:  Xavier Carnec; Mathieu Mateo; Audrey Page; Stéphanie Reynard; Jimmy Hortion; Caroline Picard; Elsie Yekwa; Laura Barrot; Stéphane Barron; Audrey Vallve; Hervé Raoul; Caroline Carbonnelle; François Ferron; Sylvain Baize
Journal:  J Virol       Date:  2018-05-29       Impact factor: 5.103

6.  Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus.

Authors:  V J La Posta; D D Auperin; R Kamin-Lewis; G A Cole
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

7.  T cell-dependence of Lassa fever pathogenesis.

Authors:  Lukas Flatz; Toni Rieger; Doron Merkler; Andreas Bergthaler; Tommy Regen; Mariann Schedensack; Lukas Bestmann; Admar Verschoor; Mario Kreutzfeldt; Wolfgang Brück; Uwe-Karsten Hanisch; Stephan Günther; Daniel D Pinschewer
Journal:  PLoS Pathog       Date:  2010-03-26       Impact factor: 6.823

8.  Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain.

Authors:  P B Jahrling; C J Peters
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

9.  Activation of the RLR/MAVS Signaling Pathway by the L Protein of Mopeia Virus.

Authors:  Lei-Ke Zhang; Qi-Lin Xin; Sheng-Lin Zhu; Wei-Wei Wan; Wei Wang; Gengfu Xiao
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

Review 10.  Reverse genetics approaches to combat pathogenic arenaviruses.

Authors:  Juan C de la Torre
Journal:  Antiviral Res       Date:  2008-09-07       Impact factor: 5.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.